Quick Answer
Estrella Immunopharma, Inc. reported Net Income of -$13.06 million for fiscal year 2025.
Estrella Immunopharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$13.06M | -78.7% |
| 2024 | -$7.31M | +34.2% |
| 2023 | -$11.11M | -1015.8% |
| 2022 | -$996.1K | -302.1% |
| 2021 | -$247.7K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.80M | -42.2% | +13.4% |
| June 30, 2025 | -$5.54M | -40.3% | -163.5% |
| March 31, 2025 | -$2.10M | -348.2% | +37.7% |
| September 30, 2024 | -$3.38M | -80.5% | +14.5% |
| June 30, 2024 | -$3.95M | -5098.5% | -741.5% |
| March 31, 2024 | -$469.5K | +82.9% | +54.0% |
| December 31, 2023 | -$1.02M | +63.0% | +45.4% |
| September 30, 2023 | -$1.87M | +35.2% | -2361.1% |
- Estrella Immunopharma, Inc. showed a decrease of -78.7% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Estrella Immunopharma, Inc.’s net income has declined by 5173.5% (from -$247.7 thousand to -$13.06 million).
- The most recent figure is from Estrella Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: